International Network of Health Promoting Hospitals and Health Services

Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders

Retrieved on: 
Tuesday, July 25, 2023
KCMG, Biobank, University, Friends, Virology, Louis Pasteur, Public, Teaching, COVID-19, Infection, Institut Pasteur Korea, Medicine, Research, Concordia University, University of North Carolina at Pembroke, International Network of Health Promoting Hospitals and Health Services, Doctor of Philosophy, Science, Entrepreneurship, Neuroscience, Laboratory, FRS, Faculty, Knowledge, Neurology, Pasteur Institute, Microbiology, Disease, Pharmaceutical industry, Nursing, Management

NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.

Key Points: 
  • NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.
  • The fellowships, the vision of Lady Mireille Gillings, are curated by an unprecedented group of international partners made up of the University of Cambridge, the University of North Carolina Gillings School of Global Public Health and Concordia University, Montreal.
  • "Future leaders in public health must have skills across what I call the 3Ms: management, money and medicine," said Lady Mireille Gillings, "The fellowships are designed to build business acumen on top of scientific experience, which is critical for the next generation of global scientists."
  • "The Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships are funded and supported by visionary leadership from Lady Mireille Gillings.

Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders

Retrieved on: 
Tuesday, July 25, 2023
KCMG, Biobank, University, Friends, Virology, Louis Pasteur, Public, Teaching, COVID-19, Infection, Institut Pasteur Korea, Medicine, Research, Concordia University, University of North Carolina at Pembroke, International Network of Health Promoting Hospitals and Health Services, Doctor of Philosophy, Science, Entrepreneurship, Neuroscience, Laboratory, FRS, Faculty, Knowledge, Neurology, Pasteur Institute, Microbiology, Disease, Pharmaceutical industry, Nursing, Management

NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.

Key Points: 
  • NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.
  • The fellowships, the vision of Lady Mireille Gillings, are curated by an unprecedented group of international partners made up of the University of Cambridge, the University of North Carolina Gillings School of Global Public Health and Concordia University, Montreal.
  • "Future leaders in public health must have skills across what I call the 3Ms: management, money and medicine," said Lady Mireille Gillings, "The fellowships are designed to build business acumen on top of scientific experience, which is critical for the next generation of global scientists."
  • "The Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships are funded and supported by visionary leadership from Lady Mireille Gillings.

CADTH Honours 2 Leaders for Outstanding Contributions to Health Technology Assessment in Canada

Retrieved on: 
Tuesday, May 16, 2023
Faculty, Agency, University, Research design, ISPOR, The Ottawa Hospital, React, Faculty of Pharmacy, University of Lisbon, HTA, Research, University of Ottawa Heart Institute, Language, International Network of Health Promoting Hospitals and Health Services, Associate, Science, Creativity, Organization, Public health, Patient, School, ISCB Senior Scientist Award, COVID-19 Response Recognition Award, ICES, Chiang Mai University, Medical device, Management, Nursing, Pharmacy, CADTH

OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.

Key Points: 
  • OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.
  • These prizes honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada's reputation for excellence in the field.
  • Brian was a key member of the international joint task group convened by the International Network of Agencies for Health Technology Assessment to lead this work.
  • Dr. Kednapa Thavorn is at the forefront of this advancement in Canada, as both a methodologist and health economist.

Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

Retrieved on: 
Monday, August 29, 2022
Muscle weakness, Lists of diseases, Security (finance), Mitochondrion, Total permanent disability insurance, Safety, INFORM, Hospital, Program, Disorder, Myopathy, Gene, Rhabdomyolysis, Brain, Disease, Death, Severe cognitive impairment, Tissue, Heart, PMM, Exercise intolerance, Deafness, DNA, Prognosis, Encephalopathy, A-DNA, U.S. Securities and Exchange Commission, Myalgia, Natural history, International Network of Health Promoting Hospitals and Health Services, GLOBE, Adenosine triphosphate, Nasdaq, Population, ATP, Adult, Parallel Walk Test, Liver, Hypoglycemia, Private Securities Litigation Reform Act, Lethargy, Metabolism, Sudden death, Mitochondrial trifunctional protein deficiency, Life, Patient, Pharmaceutical industry, Dietary supplement

The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.

Key Points: 
  • The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.
  • Improvements in 12-minute walk test distance and physical functioning scores were observed in a subgroup of patients.
  • The poster presentations elaborate on results first announced by the company in July 2022 and highlight the unmet medical need of patients with LC-FAOD.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
Death, U.S. Securities and Exchange Commission, Myopathy, Mitochondrial trifunctional protein deficiency, Disorder, Deafness, Gene, CEO, Sudden death, GLOBE, Private Securities Litigation Reform Act, Investment, Clinical trial, Brain, Encephalopathy, Myalgia, Achievement, Tissue, Enzyme, Home After Three Months Away, Life, ATP, Security (finance), PMM, Exercise intolerance, INFORM, Patient, DNA, Liver, A-DNA, Company, Prognosis, Hypoglycemia, Rhabdomyolysis, Lethargy, Program, Severe cognitive impairment, Mitochondrion, Total permanent disability insurance, STRIDE, Research, Protein, Muscle, Metabolism, Nasdaq, Heart, Conference, International Network of Health Promoting Hospitals and Health Services, Lists of diseases, Muscle weakness, Adenosine triphosphate, Pharmaceutical industry, Dietary supplement, Health insurance

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.

Key Points: 
  • IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.
  • The second quarter was a very productive period for the company, highlighted by advancements in both of our mitochondrial disease programs, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • The Company had approximately $127 million in cash, cash equivalents and short-term investments as of June30, 2022.
  • Research and development expenses for the three months ended June30, 2022 were $8.1 million, compared to $6.3 million for the three months ended June30, 2021.

Local Houston Hospital Launches Independent Provider Network

Retrieved on: 
Wednesday, June 9, 2021
Health, Primary care, Articles, Health care, Health Economics, Health care quality, Health informatics, International Network of Health Promoting Hospitals and Health Services

HOUSTON, June 9, 2021 /PRNewswire/ -- Houston Physicians' Hospital (HPH) is launching an independent provider network to bring more opportunities to physicians, providers, employers and patients.

Key Points: 
  • HOUSTON, June 9, 2021 /PRNewswire/ -- Houston Physicians' Hospital (HPH) is launching an independent provider network to bring more opportunities to physicians, providers, employers and patients.
  • We are excited about launching the network to support independent providers as we focus on providing high quality care.
  • HPH is building the network to support independent providers by working together to continue delivering clinical quality outcomes and exceptional patient experience ratings.
  • Houston Physicians' Hospital sets the standard for superior patient healthcare and satisfaction by providing personal, individualized care to the community.